Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Cardiac Arrhythmia Service, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
JACC Heart Fail. 2014 Jun;2(3):230-7. doi: 10.1016/j.jchf.2014.02.004. Epub 2014 Apr 30.
This study examined the prognostic significance of pre- and post-capillary components of pulmonary hypertension (PH) in patients receiving cardiac resynchronization therapy (CRT).
PH is common in patients with left ventricular systolic dysfunction (LVSD) receiving CRT. The impact of PH subtype on clinical outcome in CRT is unknown.
The study population consisted of 101 patients (average age 66 ± 13 years, left ventricular ejection fraction 0.23 ± 0.07, and New York Heart Association functional class 3.2 ± 0.4) who underwent right heart catheterization in the 6 months before CRT. PH was defined as a mean pulmonary artery pressure ≥25 mm Hg; a significant pre-capillary contribution to elevated mean pulmonary artery pressure was defined as a transpulmonary gradient (TPG) ≥12 mm Hg. Clinical endpoints were assessed at 2 years and included all-cause mortality and a composite of death, left ventricular assist device, or cardiac transplantation.
Patients with TPG ≥12 mm Hg were more likely to experience all-cause mortality (hazard ratio [HR]: 3.2; 95% confidence interval [CI]: 1.3 to 7.4; p = 0.009) and the composite outcome (HR: 3.0; 95% CI: 1.4 to 6.3; p = 0.004) compared with patients with TPG <12 mm Hg. After multivariate adjustment for hemodynamic, clinical, and echocardiographic variables, only TPG ≥12 mm Hg and baseline right ventricular (RV) dilation (RV end-diastolic dimension >42 mm) were associated with the composite clinical outcome (p = 0.05 and p = 0.04, respectively).
High TPG PH and RV dilation are independent predictors of adverse outcomes in patients with LVSD who are receiving CRT. RV pulmonary vascular dysfunction may be a therapeutic target in select patients receiving CRT.
本研究探讨了接受心脏再同步治疗(CRT)的患者肺高血压(PH)的毛细血管前和毛细血管后成分的预后意义。
PH 在接受 CRT 的左心室收缩功能障碍(LVSD)患者中很常见。PH 亚型对 CRT 临床结局的影响尚不清楚。
研究人群包括 101 例患者(平均年龄 66±13 岁,左心室射血分数 0.23±0.07,纽约心脏协会功能分级 3.2±0.4),他们在 CRT 前 6 个月接受了右心导管检查。PH 定义为平均肺动脉压≥25mmHg;肺动脉压升高有显著的毛细血管前贡献,定义为跨肺梯度(TPG)≥12mmHg。临床终点在 2 年内评估,包括全因死亡率和死亡、左心室辅助装置或心脏移植的复合终点。
TPG≥12mmHg 的患者更有可能经历全因死亡率(风险比[HR]:3.2;95%置信区间[CI]:1.3 至 7.4;p=0.009)和复合终点(HR:3.0;95%CI:1.4 至 6.3;p=0.004),与 TPG<12mmHg 的患者相比。多变量调整血流动力学、临床和超声心动图变量后,仅 TPG≥12mmHg 和基线右心室(RV)扩张(RV 舒张末期内径>42mm)与复合临床结局相关(p=0.05 和 p=0.04)。
高 TPG PH 和 RV 扩张是接受 CRT 的 LVSD 患者不良结局的独立预测因子。在接受 CRT 的特定患者中,RV 肺血管功能障碍可能是一个治疗靶点。